GSK has announced an agreement to acquire clinical-stage biopharmaceutical company RAPT Therapeutics for an equity value of approximately USD 2.2 billion. The acquisition centres on ozureprubart, a long-acting anti-IgE monoclonal antibody (mAb) currently in Phase IIb development for the prevention of food allergies. The therapy is designed to offer a more convenient dosing regimen with the potential for administration every 12 weeks, addressing a significant unmet need in a patient population where current treatments require injections every two to four weeks.

Food allergy is a major global health challenge, with severe reactions leading to millions of emergency room visits annually. GSK will acquire exclusive global rights to ozureprubart outside of Mainland China, Macau, Taiwan and Hong Kong, and will assume responsibility for milestone and royalty payments owed to RAPT's partner, Shanghai Jeyou Pharmaceutical. The transaction, structured as a cash tender offer followed by a merger, is expected to close in Q1 2026.

According to PharmCube's NextBiopharm® database, this marks GSK's fifth-largest M&A transaction. Click here to request a free trial for NextBiopharm®.